Sector News

Categories

Borderless Insights

Image
Negotiating terms with a new employer
Image
Borderless Executive Search welcomes New Partner, Agnieszka Ogonowska
Image
Navigating the Challenges of Expatriation: Insights from Dr. Catherine Koini and Andrew Kris

India’s Strides Arcolab to buy Shasun Pharma for $200 mln in all-stock deal

September 29, 2014
Life sciences
(Reuters) – India’s Strides Arcolab Ltd has agreed to buysmaller rival Shasun Pharmaceuticals Ltd in an all-stock deal, valued at about $200 million, to bolster its generic medicine and drug ingredient businesses.
 
Shasun, which has a market value of $193.5 million, makes drug ingredients and finished medicines, as well as provides contract research and manufacturing services. It supplies to North America, Europe, Asia and Latin America.
 
The acquisition is expected to close by June 2015, and is subject to regulatory approvals, the companies said in a stock exchange filing on Monday.
 
The deal is part of a consolidation in the pharmaceutical sector, which was expected to happen after Sun Pharmaceutical Industries Ltd agreed in April to buy local rival Ranbaxy Laboratories Ltd for $3.2 billion to create the world’s fifth largest maker of generic drugs.
 
Under the terms of the deal, Shasun shareholders will get five Strides shares for every 16 held in Shasun, the companies said in a joint statement. That values Shasun at roughly $200 million based on the stocks’ closing price on Friday.
 
The combined entity, in which Shasun shareholders will own 26 percent, will have 12 manufacturing plants and a pipeline of over 100 products, said the statement.
 
In February last year, Strides sold its injectable drugs business to U.S. firm Mylan Inc for $1.6 billion.
 
Shares in Strides rose as much as 12.8 percent to 724 rupees after the deal announcement on Monday, while Shasun ended down 0.3 percent at 196.15 rupees. The main Mumbai market index fell 0.1 percent. (Reporting by Zeba Siddiqui; additional reporting by Devidutta Tripathy; Editing by Sumeet Chatterjee and Miral Fahmy)

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

Read more
February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

Read more
February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

Read more
More news

How can we help you?

We're easy to reach